Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation

Area of Science:

• Hepatocellular Carcinoma (HCC) Research
• Clinical Prognostic Modeling
• Global Health Disparities

Background:

• Hepatocellular carcinoma (HCC) predominantly affects developing nations, often diagnosed at advanced, untreatable stages.
• Existing prognostic models for HCC necessitate resources unavailable in many low-income settings.
• There is a critical need for accessible prognostic tools in resource-limited regions.

Purpose of the Study:

• To develop and validate a straightforward clinical prognostic model for HCC.
• To utilize only easily obtainable clinical parameters and serum alpha-fetoprotein (AFP).
• To create a model applicable to Asian populations, particularly in developing countries.

Main Methods:

• Cox regression analysis was applied to clinical data and serum AFP levels from 397 HCC patients receiving supportive care.
• The model was subsequently validated using data from 324 HCC patients in an Asia-Pacific randomized trial.
• Key predictors of survival were identified through statistical modeling.

Main Results:

• Ascites, physical performance status, and serum AFP were identified as independent predictors of survival.
• A simple score was derived, categorizing patients into low-, medium-, and high-risk groups.
• The model demonstrated predictive utility in both the initial cohort and the validation group, with distinct 6-month survival rates for each risk category.

Conclusions:

• A simple, validated prognostic score for untreated HCC has been developed.
• The score relies solely on clinical assessment of ascites, physical performance status, and serum AFP measurement.
• This model is highly suitable for resource-limited settings and can aid in patient selection for clinical trials.